Loading stock data…
$39.02-1.33 (-3.30%)
Spruce Biosciences, Inc.
Spruce Biosciences, Inc. in the Healthcare sector is trading at $39.16 with a market capitalization of $170M. Wall Street consensus targets $148.00 (9 analysts), implying a +277.9% move over the next 12 months. The stock is currently near its 52-week low of $39.16, remaining 32.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.51M↓ | -$11.99M↓ | -$11.10M↓ | -$8.23M↓ | -$2.69M |
| Net Income | -$16.23M↓ | -$12.27M↑ | -$14.65M↓ | -$8.21M↓ | -$2.07M |
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, ...